Navigation Links
Infinata’s BioPharm Insight Gears Up for the 2013 American College of Cardiology Meeting with the Release of its Cardiovascular Diseases Report
Date:3/7/2013

Norwood, MA (PRWEB) March 07, 2013

As we get closer to the American College of Cardiology (ACC) meeting 9-11 March, BioPharm Insight has put together a snapshot of forward-looking cardiovascular (CV) disease coverage. To view the full report, start a free trial today.

CV-related diseases are the number one cause of death globally, with an estimated incidence rate of 17.3 million people, according to World Health Organization (WHO) 2008 statistics. Besides antiplatelets and antithrombotic therapies, oral anticoagulants have been prescribed to prevent CV disease, replacing the cumbersome standard-of-care, warfarin.

In January 2013, BioPharm Insight reported that Daiichi Sankyo's Phase III Lixiana (edoxaban) stroke prevention drug is not viewed as differentiated enough from already-approved drugs such as Boehringer Ingelheim's Pradaxa (dabigatran), Bayer/Johnson & Johnson's Xarelto (rivaroxaban) and Bristol-Myers Squibb/Pfizer's Eliquis (apixaban).

WHO's data shows 7.5 million deaths, or 13% of all CV-related deaths, can be attributed to raised blood pressure. Of those 7.5 million deaths, 51% are due to stroke and 45% are due to coronary heart disease. Cholesterol accumulation in blood vessels is a major risk factor for stroke and heart disease.

On 14 December 2012, BioPharm Insight reported that Merck's Vytorin (simvastin/ezetimibe) and Zetia (ezetimibe) cholesterol drug sales could be negatively impacted should the IMPROVE-IT CV outcomes trial for Vytorin fail to demonstrate a significant reduction in events. Experts also believe that due to the recent failure of the HPS2-THRIVE outcomes trial of Merck's "good" cholesterol-raising (HDL) drug Tredaptive, the FDA
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Infinata’s BioPharm Insight™ Achieves Record Growth in 2012
2. Infinata’s BioPharm Insight Signs 200th Media Partner, Inaugurates Advertising Program
3. Infinata’s BioPharm Insight Releases Licensing League Tables Report for 4Q12 and YE12
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
5. PDL BioPharma Announces Adjusted Conversion Rates for Its Convertible Notes
6. CeNeRx BioPharma Completes $4.85 Million Financing
7. PDL BioPharma Completes Regular Quarterly Dividend Payment
8. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
11. HealthCare Institute of New Jersey Releases 2011 Biopharmaceutical and Medical Technology Economic Impact Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)...  Array BioPharma Inc. (NASDAQ: ARRY ) today ... Novartis Pharma AG to acquire worldwide rights to encorafenib ... This agreement is conditional on the closing of transactions announced ... which are expected to close in the first half ...
(Date:1/22/2015)... January 22, 2015 GEA Niro Soavi ... top laboratory homogenizer, the PandaPLUS 2000, which is ideal ... , and cell disruption . This compact laboratory ... fruit juices, liquid food, food additives and ingredients as ...
(Date:1/22/2015)... 2015 Crystal Diagnostics (CDx) Xpress System, a ... received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing E. ... referred to as STEC or the “Big-6”) as well as ... (cfu) per 325 g of raw ground beef and raw ...
(Date:1/22/2015)... Selexis SA, a serial innovation company ... (RCBs) used for drug discovery to commercial manufacturing, announced ... Next-Generation Sequencing (NGS) data packages. The NGS ... by ensuring the integrity of the gene, validation of ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2
... to Battelle for submission of proposals to U.S. ... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a ... has announced a collaboration with Battelle, a Columbus, ... focus includes national security. Under the collaboration, Corgenix ...
... in Treatment of Skin InfectionsNEW HAVEN, Conn., Jan. ... "Company"), a development-stage company focused on the discovery ... of antibiotic-resistant infections, today announced positive final results ... novel fluoroquinolone antibiotic, delafloxacin (RX-3341), in the treatment ...
... Neuralstem, Inc. (NYSE Alternext US: CUR) today announced ... for its patent application, number 10/047,352, for Stable ... and Trade Office (USPTO). This patent covers the ... rendering its growth robust and long-lasting. , (Logo: ...
Cached Biology Technology:Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 2Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 3Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 4Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing 5Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 2Neuralstem Receives Final Notice of Allowance for New Stem Cell Immortalization Technology Patent 3
(Date:1/22/2015)... S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its ... of Washington,s Department of Licensing, in the United ... system for driver,s licenses and identification cards to its subsidiary, ... will start in January 2015, with enrollment and card production ...
(Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... of green foliage around the globe, observed since the ... part from the increasing concentration of carbon dioxide in ... the globe finds that a carbon dioxide "fertilization effect" ... 2010. Focusing on the southwestern corner of North ...
... countries have joined the International Osteoporosis Foundation (IOF) and ... Conference of Osteoporosis Patient Societies. The conference is ... Paasitorni. Osteoporosis, known as the ,silent, ... easily prone to fracture even after a minor bump ...
... that a simple program that uses pedometers to monitor how ... physical activity, decreasing sitting time, a particular problem for office ... if somebody works out 30 minutes a day, the fact ... time for the rest of the day is in and ...
Cached Biology News:Elevated carbon dioxide making arid regions greener 2Elevated carbon dioxide making arid regions greener 3IOF Worldwide Conference of Osteoporosis Patient Societies opens in Helsinki 2Study: Pedometer program helps motivate participants to sit less, move more 2
RABBIT ANTI RAT AQUAPORIN 5...
... Automatic High Sensitivity Laboratory Osmometer for both 0.2 and 2.0 mL samples for ... and record keeping. Bar code reading capability with optional scanner. RS-232 port. ... ... ...
MAb to Hu-IFN-Gamma RC2 (CD118), NON-Neutralizing, Clone MMHGR-2 Binds to but does not neutralize human interferon gamma receptor...
Recombinant Rat CINC-2 alpha, CF...
Biology Products: